Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

By L. Apetoh, François Ghiringhelli, A. Tesnière, Michel Obeid, Carla Ortiz, A. Criollo, G. Mignot, M. Maiuri, Evelyn Ullrich, P. Saulnier and 18 more. Nature Medicine, 2007

3,002 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/ca637f15ca3d66b6f975866bbd4c7e076cbaa774

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. A. Mantovani
3. M. Karin
4. A. Sica
5. Lisa M. Coussens
6. L. Galluzzi
7. L. Zitvogel
8. P. Allavena

Citations in the corpus

• Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “[44].”
• Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death (2009, background): “…evidence indicates that several chemothera- peutic agents, as well as radiotherapy, are more efficient against tumours that are implanted in immunocompetent hosts than against the same tumours growing on immuno- deficient mice (Casares et al, 2005; Apetoh et al, 2007; Obeid et al, 2007a).”
• HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4 (2012, background): “Stress conditions that induce HMGB1 secretion include hypoxia (Andrassy et al., 2008), treatment with specific antitumor drugs (Ditsworth et al., 2007), or lethal irradiation (Apetoh et al., 2007).”
• Consensus guidelines for the detection of immunogenic cell death (2014, methodology): “Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.”
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors (2009, background): “HMGB1 acts on TLR4 on DCs, and this interaction stimulates the processing of tumor antigens from dying cell”
• Immunogenic cell death and DAMPs in cancer therapy (2012, background): “These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”
• Damage-Associated Molecular Patterns in Inflammatory Diseases (2018, background): “The release of HMGB1 from dying tumor cells increased the presentation of tumor antigens and regulated the TLR4-dependent immune response (88).”